A new point of care diagnostic device that promises a revolution in diabetes management has been launched by a Surrey company.
Launched in the UK at the recent IBS Conference, the Quo-Test A1C analyser from Quotient Diagnostics is able to track blood glucose control by measuring HbA1C quickly and cost-effectively.
The blood HbA1C level indicates the average blood glucose level over a period of time. Its regular measurement is globally recognised as the gold standard for blood glucose monitoring, helping to mimimise long-term complications of diabetes and reducing the costs of treatment.
Until now, HbA1C measurement has required a laboratory test using a substantial blood sample. Designed for use in primary care, Quo-Test requires only a fingerprick drop of blood to provide rapid results.
The test involves minimal handling, and automatic calibration ensures precision and accuracy. Quo-Test has full data connectivity and can print results on a label. It can easily be transported to clinics or other community settings.
Quo-Test A1C has been certified by the National Glycohaemoglobin Standardisation Programme (NGSP).
Quotient Diagnostics Ltd is based in Walton-on-Thames.
Quo-Test